insulin glargine + metformin + sitagliptin

This is a triple combination therapy consisting of three antidiabetic agents used together for the management of type 2 diabetes mellitus. The components are: - **Insulin glargine**: A long-acting recombinant human insulin analog that provides basal glycemic control by stimulating peripheral glucose uptake and inhibiting hepatic glucose production. - **Metformin**: A biguanide oral antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal absorption of glucose, and improves insulin sensitivity. - **Sitagliptin**: An oral dipeptidyl peptidase-4 (DPP-4) inhibitor that increases incretin levels (GLP-1 and GIP), which in turn increases insulin synthesis/release from pancreatic beta cells and decreases glucagon secretion from alpha cells. This combination is not available as a single fixed-dose product but is used in clinical practice as an intensification strategy for patients with type 2 diabetes inadequately controlled on dual therapy. Clinical studies have shown improved glycemic control when all three agents are combined compared to dual regimens[4][6][8].

Other names

insulin glargine plus metformin plus sitagliptintriple therapy with insulin glargine/metformin/sitagliptin